Viking Therapeutics
Viking Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company utilizes its proprietary research platform to develop therapeutic candidates addressing indications such as non-alcoholic steatohepatitis (NASH), lipid metabolism disorders, and endocrine-driven obesity, featuring leading clinical candidates like VK2809 and VK2735. Its core operations encompass preclinical pharmacology, molecular engineering, and clinical trial advancement. As a clinical-stage development firm, the company generates minimal commercial revenue and relies on equity financing and capital markets to fund its ongoing drug development pipeline. Viking Therapeutics holds an emerging position in metabolic disease therapeutics. The company is headquartered in San Diego, California, United States, and its common stock trades on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Viking Therapeutics.
- Legal name
- Viking Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding Viking Therapeutics
- DNB Bioteknologi — DNB · 2.25 % (full portfolio disclosed, September 2026)
- JPM US Small Cap Growth Fund — JPM · 0.3 % (full portfolio disclosed, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)